Cutting-Edge HeartCare and AlloMap Solutions Featured at ISHLT 2019
BRISBANE, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that new data from studies on AlloMap and HeartCare will be featured in seven podium and poster presentations at ISHLT 2019, the annual meeting of the International Society for Heart and Lung Transplantation (ISHLT) in Orlando, FL on April 3-6, 2019.
CareDx continues a 20 year dedication to research and development in transplantation with the data to be presented at ISHLT. “CareDx has been a partner in heart transplantation for over a decade. I am glad to be part of this next wave of innovation with HeartCare surveillance to detect cardiac transplant rejection,” said Jon A. Kobashigawa, M.D., Director of the Heart Transplant Program of Cedars-Sinai.
CareDx will host a lunch a lunch symposium titled “HeartCare: Comprehensive Surveillance for Personalized Transplant Care” on Thursday, April 4, 2019, 12:00 p.m. – 1:45 p.m. at the Loews Sapphire Falls Resort. The symposium features six leaders in the transplant field:
-- Jon Kobashigawa, MD, Cedars-Sinai -- Kiran Khush, MD Stanford University -- Shelley Hall, MD, Baylor Scott & White -- Eugene DePasquale, MD, UCLA -- Sean Pinney, MD, Mount Sinai -- Mary Beth Maydosz, NP, Inova
CareDx’s HeartCare and AlloMap surveillance tests will also be featured in the following oral presentations and posters during ISHLT 2019:
Distinct Patterns of Gene Expression Identified Longitudinally and within AlloMap Score Ranges are Associated with Clinical Outcomes. Alexandre Loupy, MD: Hospital Necker, Paris, France.
Are Gene Expression Profile Testing Scores Associated with New Onset Cardiac Allograft Vasculopathy. Anuradha Lala-Trindade, MD: Medicine, Cardiology, Polulation Health Science, Icahn School of Medicine Mount Sinai, Mount Sinai Hospital, New York.
Differential Gene Expression by Race and Impact on Risk after Heart Transplantation. Yas Moayedi, MD: Medicine, Stanford University.
Does Donor-Derived Cell-Free DNA Detect the Development of De Novo Donor-Specific Antibodies. J. Patel, MD: Smidt Heart Institution at Cedars-Sinai.
Use of dd-cfDNA in Multiorgan Transplantation. Eugene C. DePasquale, MD: Department of Medicine-Cardiology, University of California, Los Angeles.
Use of dd-cfDNA in Real World Practice: Single Center Experience. Eugene C. DePasquale, MD, PhD: Department of Medicine-Cardiology, University of California, Los Angeles.
Combination of Cell-Free DNA with Gene-Expression Profiling in the Diagnosis of Acute Rejection (Abstract #975). Eugene C. DePasquale, MD, PhD: Department of Medicine-Cardiology, University of California, Los Angeles. 6:00 p.m. – 7:15 p.m., Hibiscus 2.
“CareDx is committed to providing best-in-class solutions for transplant patients,” said Peter Maag, Chief Executive Officer at CareDx. “These abstracts highlight CareDx’s position as a leading provider of genomics-based information in transplantation, with the goal to improve long-term patient outcomes. We collaborate with the many distinguished clinicians in transplantation, and look forward to having them share their latest insights with the broader community at ISHLT.”
About CareDx CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products along the pre- and post-transplant testing continuum, and is the leading provider of genomics-based information for transplant patients.
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements, including statements regarding the Company’s participation at ISHLT. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including general economic and market factors, among others discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed by CareDx with the SEC on March 6, 2019 and the periodic reports that CareDx has subsequently filed with the SEC. Any of these may cause CareDx’s actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
CareDx, Inc.Sasha KingChief Commercial Officer415-287-2393 firstname.lastname@example.org
Investor RelationsDavid ClairIntegrated Corporate Relations, Inc.646-277-1266 email@example.com